The in vivo effect of rabbit anti-AKR mouse brain-associated serum (RAMB) was determined on theta bearing lymphocytes present in the spleens and thymuses of mature C3H mice and AKR mice staged into preleukemic, leukaemic and overtly leukaemic states. Following seven daily injections of RAMB serum, the splenic plaque-forming cell (PFC) response to sheep erythrocytes (SRBC) and the percentage of theta-bearing lymphocytes in the spleen were significantly decreased in the C3H and the preleukaemic AKR mice. Decreases in thymic weight and thymocyte numbers were also apparent. Determinations of theta antigen density using in vitro cytoxicity tests indicated that splenic and thymic T lymphocytes (thymus-derived) remaining in the RAMB-treated C3H and preleukemic AKR mice consisted primarily of cells bearing less of the theta surface antigen. Histopathological studies of tissues from these two treated groups revealed cortical lymphocyte depletion in the thymus, and marginal and periarteriolar depletion in the spleen. Leukaemic AKR mice, administered seven injections of RAMB serum, demonstrated less dramatic changes in thymus weight, histopathology and theta-bearing cell percentages when compared with the data from the preleukaemic AKR or matureC3H mice. The results from testing overtly luekaemic AKR mice administered RAMB serum for the 7 or 9 days did not demonstrate differences from findings from groupsof overtly leukaemic control mice. These data indicate that the in vivo activity of RAMB serum in C3H mice and preleukaemic AKR mice is directed primarily toward the less mature T-lymphocyte population. This influence of RAMB serum is lesspronounced in leukaemic and the more overtly leukaemic mice, suggesting that a decreasedpopulation of RAMB-susceptible lymphocytes are present in these animals.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1445851PMC

Publication Analysis

Top Keywords

akr mice
28
ramb serum
20
mice
12
overtly leukaemic
12
preleukaemic akr
12
theta bearing
8
bearing lymphocytes
8
akr
8
c3h mice
8
leukaemic overtly
8

Similar Publications

Streptococcus pneumoniae and influenza A virus (IAV) are significant agents of pneumonia cases and severe respiratory infections globally. Secondary bacterial infections, particularly by Streptococcus pneumoniae, are common in IAV-infected individuals, leading to critical outcomes. Despite reducing mortality, pneumococcal vaccines have high production costs and are serotype specific.

View Article and Find Full Text PDF
Article Synopsis
  • * Various assays demonstrated that reducing AKR1B1 levels inhibited the growth and survival of acute leukemia cells, confirming its high expression in these cells and its role in promoting cell proliferation and preventing apoptosis.
  • * RNA-sequencing revealed that AKR1B1 affects the expression of certain genes linked to leukemia, and combining AKR1B1 knockdown with EZH2 inhibition showed a promising synergistic effect, indicating that targeting AKR1B1 may be a new therapeutic approach for treating acute leukemia.
View Article and Find Full Text PDF

Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance.

Cancer Cell

December 2024

Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA; Graduate Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA. Electronic address:

Article Synopsis
  • Immune checkpoint blockade (ICB) can induce tumor ferroptosis, but many patients don't respond because tumors evade this process within the tumor microenvironment (TME).
  • Researchers found that SLC13A3 acts as a transporter for itaconate in tumor cells, contributing to resistance against ferroptosis, which weakens tumor immunity and reduces ICB effectiveness.
  • Targeting SLC13A3 through various methods, like genetic alteration or using a specific inhibitor, can sensitize tumors to ferroptosis, slow down tumor growth, and enhance the effectiveness of ICB treatments, highlighting SLC13A3 as a potential target for cancer therapy.
View Article and Find Full Text PDF

Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice.

J Thromb Haemost

January 2025

Cardeza Foundation for Hematologic Research, Department of Medicine, Division of Hematology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

Background: Phosphatidylserine (PS) is a procoagulant phospholipid enriched on surfaces of activated vascular cells including platelets, endothelium, monocytes, and microvesicles. As a molecular driver of thrombosis accessible to drug blockade, PS is an attractive pharmacologic target for modulating thrombogenesis, with potentially reduced bleeding risk compared to anticoagulant and antiplatelet therapies.

Objectives: Test antithrombotic capabilities of a liposomal formulation, Zn-dipicolylamine cyanine-3[22,22]/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (molar ratio, 3:97), designated as DPAL, which we previously described binds selectively to PS-enriched cell surfaces, compared with effects on bleeding, in mouse models.

View Article and Find Full Text PDF

Relocalizing transcriptional kinases to activate apoptosis.

Science

October 2024

Department of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA.

Kinases are critical regulators of cellular function that are commonly implicated in the mechanisms underlying disease. Most drugs that target kinases are molecules that inhibit their catalytic activity, but here we used chemically induced proximity to convert kinase inhibitors into activators of therapeutic genes. We synthesized bivalent molecules that link ligands of the transcription factor B cell lymphoma 6 (BCL6) to inhibitors of cyclin-dependent kinases (CDKs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!